% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Davies:891766,
author = {Davies, Nigel and Hovdal, Daniel and Edmunds, Nicholas and
Nordberg, Peter and Dahlén, Anders and Dabkowska,
Aleksandra and Arteta, Marianna Yanez and Radulescu, Aurel
and Kjellman, Tomas and Höijer, Andreas and Seeliger, Frank
and Holmedal, Elin and Andihn, Elisabeth and Bergenhem, Nils
and Sandinge, Ann-Sofie and Johansson, Camilla and Hultin,
Leif and Johansson, Marie and Lindqvist, Johnny and
Björsson, Liselotte and Jing, Yujia and Bartesaghi, Stefano
and Lindfors, Lennart and Andersson, Shalini},
title = {{F}unctionalized lipid nanoparticles for subcutaneous
administration of m{RNA} to achieve systemic exposures of a
therapeutic protein},
journal = {Molecular Therapy / Nucleic Acids},
volume = {24},
issn = {2162-2531},
address = {New York, NY},
publisher = {Nature Publ. Group},
reportid = {FZJ-2021-01724},
pages = {369 - 384},
year = {2021},
abstract = {Lipid nanoparticles (LNPs) are the most clinically advanced
delivery system for RNA-based drugs but have predominantly
been investigated for intravenous and intramuscular
administration. Subcutaneous administration opens the
possibility of patient self-administration and hence
long-term chronic treatment that could enable messenger RNA
(mRNA) to be used as a novel modality for protein
replacement or regenerative therapies. In this study, we
show that subcutaneous administration of mRNA formulated
within LNPs can result in measurable plasma exposure of a
secreted protein. However, subcutaneous administration of
mRNA formulated within LNPs was observed to be associated
with dose-limiting inflammatory responses. To overcome this
limitation, we investigated the concept of incorporating
aliphatic ester prodrugs of anti-inflammatory steroids
within LNPs, i.e., functionalized LNPs to suppress the
inflammatory response. We show that the effectiveness of
this approach depends on the alkyl chain length of the ester
prodrug, which determines its retention at the site of
administration. An unexpected additional benefit to this
approach is the prolongation observed in the duration of
protein expression. Our results demonstrate that
subcutaneous administration of mRNA formulated in
functionalized LNPs is a viable approach to achieving
systemic levels of therapeutic proteins, which has the added
benefits of being amenable to self-administration when
chronic treatment is required.},
cin = {JCNS-FRM-II / MLZ / JCNS-1 / JCNS-4},
ddc = {610},
cid = {I:(DE-Juel1)JCNS-FRM-II-20110218 / I:(DE-588b)4597118-3 /
I:(DE-Juel1)JCNS-1-20110106 / I:(DE-Juel1)JCNS-4-20201012},
pnm = {6G4 - Jülich Centre for Neutron Research (JCNS) (FZJ)
(POF4-6G4) / 632 - Materials – Quantum, Complex and
Functional Materials (POF4-632)},
pid = {G:(DE-HGF)POF4-6G4 / G:(DE-HGF)POF4-632},
experiment = {EXP:(DE-MLZ)KWS2-20140101},
typ = {PUB:(DE-HGF)16},
pubmed = {33868782},
UT = {WOS:000658506500001},
doi = {10.1016/j.omtn.2021.03.008},
url = {https://juser.fz-juelich.de/record/891766},
}